In summary, the therapeutic modulation of protein S-nitrosylation offers a compelling new avenue to overcome resistance and reinvigorate anti-tumor immunity in NRAS-mutant melanoma, warranting further preclinical and clinical investigation. Here, NRAS is linked to melanoma.